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Abstract: Schistosome parasites kill 250,000 people every year.  Treatment of schistosomiasis relies 16 
on the drug praziquantel. Unfortunately, a scarcity of molecular tools has hindered the discovery of 17 
new drug targets.  Here, we describe a large-scale RNA interference screen in adult Schistosoma 18 
mansoni examining the function of 2,216 genes.  We discovered 250 genes with phenotypes affecting 19 
neuromuscular function, tissue integrity, stem cell maintenance, and parasite survival.  Leveraging 20 
these data, we prioritize compounds with activity against the parasites and uncover a pair of protein 21 
kinases (TAO and STK25) that cooperate to maintain muscle-specific mRNA transcription.  Loss of 22 
either of these kinases results in paralysis and worm death in a mammalian host.  These studies may 23 
help expedite therapeutic development and invigorate studies of these neglected parasites.   24 
 25 
One Sentence Summary: An RNAi screen examines the function of 20% of S. mansoni genes uncovering 26 
new phenotypes and suggesting new therapeutic targets. 27 
 28 
Main Text: Studies of gene function in intra-mammalian schistosome parasites have been limited to 29 
relatively small numbers of genes(1). Therefore, we developed a large-scale RNAi screening platform on 30 
adult schistosomes that prioritized a list of 2,320 of the worm’s ~10,000 protein coding genes (Fig. S1A, 31 
Table S1). We generated dsRNAs, and treated adult male and female pairs with dsRNA over the course of 32 
a 30-day experiment (Fig. 1A). After filtering genes that either did not amplify by PCR, or failed to generate 33 
sufficient concentrations of dsRNA, a total of 2,216 genes were screened (Table S1). 34 
Schistosomes live in the veins surrounding the host intestines, and attach to the vascular endothelium 35 
to avoid being swept away in the blood and trapped in host organs. Under in vitro culture conditions healthy 36 
parasites attach to the substrate with a combination of their oral and ventral suckers (Movie S1). We thus 37 
reasoned that substrate attachment would be a useful quantitative metric to define RNAi treatments that 38 
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affect parasite vitality and predict in vivo survival. Therefore, we monitored parasites for 30 days to identify 39 
substrate attachment and other visible defects.  40 
Schistosomes possess adult somatic stem cells (neoblasts) that rejuvenate parasite tissues, including 41 
the intestine and tegument (skin)(2, 3). The parasites also contain large numbers of proliferative germline 42 
stem cells (GSCs) in their reproductive organs(2) which are essential for producing eggs; the central driver 43 
of parasite-induced pathology in vivo(4). Therefore, we monitored the maintenance of neoblasts and GSCs 44 
by labeling parasites with the thymidine analog EdU prior to the conclusion of the experiment (Fig. 1A). 45 
Due to the variable rate at which the reproductive organs of female worms degenerate during in vitro 46 
culture(5), stem cell proliferation was only monitored in male worms. For genes with RNAi phenotypes 47 
uncovered during our screen, we confirmed gene identity by sequencing, and mitigated potential off-target 48 
effects by designing an additional dsRNA targeting a non-overlapping gene region or by examining 49 
sequence identity of hits with other S. mansoni genes (Fig. S1).  These studies identified 195 genes with 50 
fully-penetrant attachment phenotypes of which 121 possessed phenotypes in addition to attachment, 51 
including: tissue and intestinal edema (36), head (26) and/or tegument (78) degeneration, muscular 52 
hypercontraction (6), and death (36) (Fig. 1B, Table S2). RNAi of an additional 66 genes resulted in stem 53 
cell maintenance defects but caused no other visible phenotypes (e.g., attachment) suggesting an essential 54 
role for stem cell maintenance (Fig. S2, Table S3).  We cannot rule out the possibility of false negatives 55 
among the genes with no phenotype and encourage greater scrutiny of such genes by alternate knockdown 56 
approaches or analysis of different phenotypic readouts. 57 
 Of the 66 genes required for stem cell survival, RNAi of over 90% (60/66) led to defects in the 58 
maintenance of both proliferative cells in the male testes and neoblasts (Fig. S2). However, for a minority 59 
of genes this maintenance defect appeared to be specific to either proliferative cells in the testes or the 60 
neoblasts (Fig. S2). Gene Ontology enrichment analysis identified genes important for protein translation, 61 
including gene products involved in ribosomal structure, tRNA aminoacylation, and rRNA processing as 62 
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putative regulators of proliferative cell maintenance (Fig. S3A). Although this could reflect an enhanced 63 
sensitivity of actively proliferating cells to alterations in protein translation, studies have highlighted “non-64 
housekeeping” roles for translational regulators in controlling stem cell function(6).  65 
Of the 195 genes essential for parasite attachment, a large fraction share sequence similarity with 66 
other organisms, including other medically-relevant schistosome species (Table S4).  Additionally, most 67 
genes with an attachment phenotype (172/195 genes; 88%) possess a close homolog from C. elegans or D. 68 
melanogaster that likewise has a loss-of-function phenotype (Table S5). Gene Ontology analyses of genes 69 
with attachment phenotypes further revealed that the dominant group of enriched genes were those encoding 70 
components necessary for protein turnover via the ubiquitin-proteasome system (UPS) (Fig. S3B).  71 
Proteolysis is important for larval and adult viability in vitro(7, 8) and our data identified that key 72 
components from virtually every arm of the UPS were required for adult parasite vitality during in vitro 73 
culture (Fig. S4A).  Indeed, RNAi of nearly all of UPS components resulted in extensive tissue degeneration 74 
and in some cases adult parasite death (Fig. S4B-C).  75 
To determine if any genes associated with attachment phenotypes encoded proteins targeted by 76 
existing pharmacological agents, we searched the literature and the ChEMBL database(9) (Table S6). This 77 
analysis uncovered 205 compounds potentially targeting 49 S. mansoni proteins. We selected 14 of these 78 
compounds (Table S7) and examined the activities of these compounds on worms cultured in vitro either 79 
by automated worm movement tracking or parasite attachment. More than half of the compounds tested 80 
(8/14) on worms at 10 µM reduced parasite movement >75% and half of the compounds (7/14) caused 81 
fully-penetrant substrate attachment defects by D7 post-treatment (Fig. 2A-B, Movie S2).  Similarly, 7 of 82 
these compounds affected the movement of post-infective larvae (schistosomula), suggesting activity 83 
against multiple life-cycle stages (Table S8). 84 
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Among the compounds that emerged from these studies was simvastatin, an HMG-CoA reductase 85 
inhibitor, with known effects on parasites both in vitro and in vivo(10). The proteasome inhibitor ixazomib 86 
affected both schistosome movement (Fig. 2A) and attachment (Fig. 2B), mirroring a recent report using 87 
the proteasome inhibitor bortezomib (7).   However, the most potent effects on adult parasites were observed 88 
with CB-5083 and NMS-873 that inhibit the UPS component p97 by either competing with ATP (11) or 89 
binding to an allosteric site(12), respectively (Fig. S5A). Similar to the death observed following long-term 90 
p97 RNAi treatment (Fig. 1B), both p97 inhibitors led to death in vitro (Movie S3).  Despite their distinct 91 
biochemical mechanisms of action, we noted similar deformations in the structure of the parasite tegument 92 
following treatment with either CB-5083 or NMS-873, suggesting that these compounds have similar 93 
pharmacological effects on the parasite (Fig. 2C).  94 
We then assessed if NMS-873 and CB-5083 affected UPS function by measuring the accumulation 95 
of ubiquitinated proteins using an antibody that recognizes K48 polyubiquitinated proteins marked for 96 
proteasome-mediated destruction(13). We observed the accumulation of polyubiquitinated proteins 97 
following RNAi of p97 and after treatment of schistosomes with either CB-5083 or NMS-873 (Fig. S5B).  98 
Consistent with CB-5083 or NMS-873 acting via p97 inhibition to blunt protein degradation, we found that 99 
p97 RNAi-treatment together with low concentrations of either drug led to additive increases in 100 
polyubiquitinated protein accumulation (Fig.  S5C).  We also observed accumulation of polyubiquitinated 101 
proteins following either RNAi of proteasome subunit beta type-2 or treatment with ixazomib (Fig. S5D).  102 
These effects on the degradation of ubiquitinated proteins appeared to be specific to inhibition of UPS 103 
function, rather than a non-specific effect due to reduced worm vitality (Fig. S5D).  104 
We then depleted UPS components using RNAi and surgically transplanted these worms into the 105 
mesenteric veins of recipient mice (Fig. S6A) and measured parasite egg deposition in host tissues and 106 
parasite survival.  Following hepatic portal perfusion, we recovered about 55% of transplanted control 107 
RNAi-treated worms (Figs. 2D, S6B) and these parasites established patent infections, depositing large 108 
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number of eggs into the livers of recipient mice (Figs. 2E, S6C-D).  In contrast, we failed to recover 109 
parasites following hepatic portal perfusion from mice receiving p97 (Fig. 2D) or proteasome subunit beta 110 
type-2 (Fig. S6B). As a consequence, the livers in these mice were devoid of eggs and we observed no signs 111 
of egg-induced granulomas (Figs. 2E, S6C-D).  We also observed RNAi-treated parasites at various stages 112 
of infiltration by host immune cells (Fig. S6E-F). This suggests that these parasites are unable to remain in 113 
the portal vasculature and are cleared via the liver by the immune system.  Taken together, these data 114 
highlight the essentially and druggability of the schistosome UPS.   115 
Another group of potentially druggable targets to emerge from our RNAi screen were protein 116 
kinases, 19 of which led to defects in either parasite attachment or stem cell maintenance. RNAi of two 117 
STE20 serine-threonine kinases: tao and stk25, which are homologs of the human TAO1/2/3 and 118 
STK25/YSK1 protein kinases, respectively, led to rapid detachment from the substrate (Fig. S7A) and a 119 
concomitant posterior paralysis and hypercontraction of the body, such that the parasites took on a 120 
distinctive banana-shaped morphology (Figs. 3A, S7B, Movie S4).  Aside from RNAi of stk25 and tao, this 121 
banana-shaped phenotype of worms was unique, only observed following RNAi of a CCM3/PDCD10 122 
homolog (Smp_031950), a known heterodimerization partner with the mammalian STK25 kinase(14).  We 123 
failed to observe death of either stk25- or tao- depleted parasites during in vitro culture. However, following 124 
surgical transplantation, we noted a reduction in the recovery of tao or stk25 RNAi-treated parasites from 125 
recipient mice and these recipient mice displayed few signs of egg-induced granuloma formation (Figs. 3B-126 
C, S7C-D).  Thus, both tao and stk25 appear to be essential for schistosome survival in vivo.   127 
Given the unique and specific nature of the stk25 and tao associated “banana” phenotype we 128 
reasoned that these kinases may be acting in concert to mediate signaling processes in the worm.  The 129 
Drosophila STK25 ortholog (GCK3) is a substrate of TAO and these proteins function in a signaling 130 
cascade essential for tracheal development(15).  Likewise we observed that recombinant S. mansoni STK25 131 
(SmSTK25) could serve as a substrate for the S. mansoni TAO (SmTAO) in an in vitro kinase assay (Fig. 132 
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S8A-B).  The human STK25 is activated by phosphorylation of a conserved threonine residue within its 133 
activation loop(16).  By mass spectrometry we observed that this conserved threonine within the predicted 134 
SmSTK25 activation loop (T173) was phosphorylated following incubation of recombinant SmTAO with 135 
catalytically inactive SmSTK25 (Fig. S8C-D). Using an antibody that recognizes activation loop 136 
phosphorylation in STK25 orthologs(16), western blotting revealed SmSTK25 T173 autophosphorylation 137 
following an in vitro kinase reaction; this signal was abrogated in controls lacking ATP and when the 138 
SmSTK25 catalytic K48 residue was mutated to R (Figs. 3D, S8E).  Consistent with our mass spectrometry 139 
results, we detected robust phosphorylation of T173 when recombinant SmTAO was incubated with kinase 140 
dead SmSTK25 (Fig. 3D), suggesting that SmTAO can phosphorylate a key residue for the activation of 141 
the mammalian STK25.    142 
We reasoned that the schistosome TAO and STK25 might be acting in a signaling module to mediate 143 
critical processes in the parasite.  To define these processes, we performed transcriptional profiling on 144 
RNAi-treated parasites just prior to observing detachment and hypercontraction (Day 6 and Day 9 for tao 145 
and stk25 RNAi treatments, respectively) (Fig. S9A-B).  We found that expression of differentially 146 
regulated genes following RNAi of either tao or stk25 were correlated (Fig. 3E) and that more than half of 147 
these differentially regulated genes were common in both datasets (Fig. S9C, Table S9).  Importantly, 148 
RNAi of either tao or stk25 was specific, not affecting expression of the other kinase gene of this pair (Fig. 149 
3E-F).   150 
Examining the tissue-specific expression of differentially-regulated genes on an adult schistosome 151 
single cell expression atlas using cells from schistosome somatic tissues(17), we found that roughly 40% 152 
(51/129) of the most down-regulated genes following tao and stk25 RNAi were specific markers of parasite 153 
muscle cells (Fig. S10A-C, Table S9).  Indeed, nearly half of all mRNAs specifically-enriched in muscle 154 
cells (60/135) from this single cell atlas, including key muscle contractile proteins, were down-regulated 155 
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following RNAi of both tao and stk25 (Figs. 3F, S10B, D, Table S10).  Importantly, these transcriptional 156 
effects appeared to be largely specific to parasite muscles (Figs. 3F, S10B, Table S10).   157 
In principle, loss of muscle-specific mRNAs could be due to either loss of muscle cells or down-158 
regulation of muscle-specific mRNAs.  We thus labeled F-actin in schistosome muscle fibers with 159 
phalloidin and performed in situ hybridization to detect muscle-specific mRNAs. RNAi-treated parasites 160 
exhibited a reduction in the expression of mRNAs encoding the contractile proteins Tropomyosin 1 and a 161 
Myosin Light Chain by in situ hybridization (Fig. 3G), but no qualitative defects in phalloidin staining of 162 
body wall muscles (Fig. S11).  Thus, it appears that these kinases are required to maintain the transcription 163 
of many muscle-specific mRNAs in intact muscle cells.  Interestingly, the heads of tao and stk25 RNAi 164 
parasites retained their capacity for movement (Movie S4) and partially maintained the expression of 165 
muscle-specific mRNAs (Fig. 3G).  Thus, there appears to be a relationship between the maintenance of 166 
muscle-specific mRNA expression and locomotion.   167 
Taken in their entirety, our data suggest that STK25 and TAO kinases cooperate in the schistosome 168 
to mediate signaling essential for sustaining the transcription of muscle-specific mRNAs.  As a 169 
consequence, loss of either SmSTK25 or SmTAO activity results in muscular function defects 170 
compromising parasite survival in vivo.  As whole-body knockouts of mouse STK25 are homozygous viable 171 
displaying no obvious deleterious phenotypes(18), SmSTK25 represents an attractive target for therapeutic 172 
intervention.  Similar cross-examination of genes associated with other phenotypic classes (e.g., tissue 173 
edema) may provide insights into the specificity of the various phenotypes observed in this work.   174 
Technological advances have paved the way for large-scale analyses of gene function in protozoan 175 
parasites(19-21), but, have been lacking in helminth parasites. Our systematic analysis of gene function in 176 
schistosomes allowed us to effectively prioritize targets and potential specific inhibitors with activities on 177 
worms.  Future efforts should not only further explore the potency and selectivity of compounds our studies 178 
have uncovered (Fig. 2A-B, Table S6), but larger libraries of compounds with known molecular targets 179 
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(22).  However, to mitigate potential issues with host toxicity it is also worth exploring whether parasite-180 
selective inhibitors of validated target proteins can be uncovered.  Not only does this study enhance our 181 
understanding of schistosome biology, it provides a new lens to prioritize genes of interest in other 182 
medically- and agriculturally-important parasitic flatworms.  Collectively, we anticipate this study will 183 
expedite the discovery of new anti-helminthics.    184 
 185 
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Fig. 1. Summary of RNAi phenotypes.  339 
(A) RNAi treatment regime.  Parasites were monitored for visible abnormalities and at D29 EdU was added 340 
to media to label proliferative cells. (B) Categories of RNAi phenotypes observed. kin-17 (Smp_023250), 341 
cog1 (Smp_132980), p97 (Smp_018240), c44 (Smp_136260), prpf4b (Smp_068960), gtf2f1 342 
(Smp_088460), stk25 (Smp_096640). Scale bar: 100 µm 343 
 344 
Fig. 2.  Compounds prioritized from RNAi studies have effects on schistosomes in vitro.   345 
(A) Compounds (red text) predicted to target schistosome proteins (blue text) essential for parasite 346 
attachment at 10 µM for their effects on worm motility. n = 12 worm pairs, n = 3 biological replicates; data 347 
are mean +/- SD.  Dashed line, threshold for 75% reduction in motility (B) Heatmap showing time course 348 
measuring the fraction of male worms attached to the substrate following treatment with compounds for 72 349 
hours as in A. n = 3 biological replicates (C) Effects of CB-5083 or NMS-873 (10 µM, 72 hrs) treatment 350 
on male parasites. (D) Percent recovery p97(RNAi) or control(RNAi) male parasites surgically transplanted 351 
into mice. n = 8 transplants for each group. ****, p < 0.0001, t-test; data are mean +/- 95% CI. (E) 352 
Hematoxylin and Eosin staining of livers from mice receiving control or p97(RNAi) parasites. Egg-induced 353 
granulomas (yellow arrows).  (top right) counts of eggs/cm liver section are shown, counts from sections 354 
from  n = 3 livers. Scale bars: C, E, 100 µm. 355 
 356 
Fig. 3. The protein kinases SmSTK25 and SmTAO are essential to maintain muscular function  357 
 18 
(A) RNAi of stk25 or tao causes parasite hypercontraction. (B-C) Percent recovery stk25(RNAi), 358 
tao(RNAi), or control(RNAi) male parasites surgically transplanted into mice. n > 11 transplants for each 359 
group. ****, p < 0.0001, t-test; data are mean +/- 95% CI. (D) Western blot to detect phospho-T173 (p-360 
SmSTK25) or total SmSTK25 following an in vitro kinase reaction +/- ATP. kinase dead 361 
SmTAO(kdSmTAO).  Representative of n = 2 experiments. (E) Scatter plot showing the relationship 362 
between the differentially expressed genes (p adj < 0.001, Benjamini-Hochberg corrected Wald test) 363 
following stk25 or tao RNAi-treatment (r = 0.9, p < 0.0001, Pearson correlation). (F) Heatmap showing 364 
expression of tissue-specific transcripts following RNAi of tao or stk25. (G). in situ hybridization for 365 
tropomyosin 1 (tpm1, Smp_340760) and a myosin light chain (myl2, Smp_132670) following RNAi at D13.  366 
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Materials and Methods 
Parasites 
Adult S. mansoni (NMRI strain) (6–7 weeks post-infection) or juvenile worms (4–5 weeks post-infection) 
were harvested from infected female Swiss Webster mice by hepatic portal vein perfusion with 37°C 
DMEM (Mediatech, Manassas, VA) plus 8% Horse Serum and heparin. Parasites were rinsed in DMEM + 
plus 8% Horse Serum and cultured (37°C/5% CO2) in Basch's Medium 169(23) and 1× Antibiotic-
Antimycotic (Gibco/Life Technologies, Carlsbad, CA 92008).  Experiments with and care of vertebrate 
animals were performed in accordance with protocols approved by the Institutional Animal Care and Use 
Committee (IACUC) of UT Southwestern Medical Center (approval APN: 2017-102092).   
 
RNAi screen 
For our screen we prioritized genes that were expressed in adult male schistosome somatic tissues (using 
an existing expression dataset (3)).  This prioritized list included genes encoding enzymes, cell-surface 
receptors, ion channels, to enrich for proteins with potential druggability, and hypothetical proteins of 
unknown function, to ascribe function to these genes. However, early iterations of RNAi screening found 
that positive PCR products could not be obtained for ~30% of gene models from v5 of the S. mansoni 
genome.  To ensure a large fraction of PCRs yielded products we manually curated gene models to define 
stretches of mRNA sequence supported by experimental data.  Using these manually curated stretches of 
sequence, primers were designed to amplify ~700 bp fragments using BatchPrimer3 
http://batchprimer3.bioinformatics.ucdavis.edu/index.html. For gene fragments shorter than 700 bp, 
primers were designed to cover as much of the transcript as possible.  For reverse transcription of double 
stranded RNAs, a T7 promoter sequence (GAATTTAATACGACTCACTATA) was added to the 5’ end of 
each oligo.  To facilitate DNA sequencing of cDNAs associated with RNAi phenotypes, we added a NotI 
or AscI restriction enzyme site between the T7 and gene-specific sequences on the forward and reverse 
oligos, respectively.  These oligos were synthesized and packaged in 96-well plates and used for PCR using 
adult schistosome cDNA as a template.  5 µL of PCR products were then used for in vitro transcription to 
generate dsRNA in 100 µL as previously described (24). After overnight incubation at 37 ºC, dsRNAs were 
annealed by a successive 3-min gradient incubation at 95 ºC, 75 ºC, and 55 ºC, then cooled down at room 
temperature for 5 min.  The presence and size of PCR products and dsRNA were all analyzed by agarose 
gel electrophoresis and samples stored at -20 ºC. For RNAi treatments, approximately 5 pairs of adult 
parasites were placed in 3 mL Basch 169 media in a 12-well plate and treated with 20 µL dsRNA at D0, 
D2, D9, D16 and D23. To examine cell proliferation, the media were supplemented with EdU (10 µM) at 
D29.  On day 30, videos were captured for RNAi treatments that caused visible RNAi phenotypes and after 
video acquisition all parasites were fixed and processed for EdU detection (2).  During the entire 30D RNAi 
treatment regime, media was changed every 1-2 days and worm attachment and morphological changes 
were monitored.   
 
To validate the identity of hits from the initial RNAi screening, the original PCR products were digested 
with NotI (NEB) for 30 min at 37 ºC, gel purified (Zymoclean Gel DNA Recovery Kit), and sequenced 
with a T7 primer.   Sequences of genes validated by sequencing were uploaded into BatchPrimer3 to design 
new primers that amplify a fragment sharing no overlap with the PCR products from the initial RNAi 
screening. In cases where genes sequences were too short to design non-overlapping amplicons, we retained 
the original primer sequences. These primers were synthesized without further modification, used to 
generate PCR products, and then inserted into pJC53.2 using TA cloning (24).  These plasmids were 
purified from E. coli, validated by sequencing, and used as a template to generate dsRNA.  We then repeated 
the RNAi treatment regime used in the original screen.  In order to be considered a hit a gene had to display 
a similar and fully-penetrant phenotype in at least three independent experiments conducted on separate 
days from different liver perfusions using distinct batches of dsRNA. 
 
Parasite labelling and imaging 
 
 
Whole-mount in situ hybridization (3), EdU detection (2), and phalloidin staining (25) were performed as 
previously described. For in situ hybridization, riboprobes were generated from cDNA fragments amplified 
using primers for tropomyosin-1 (Smp_340760, gagaaagagaatgctatggaaagagc/cctcattttgtagtttagatacttgacg) 
or myosin light chain (Smp_132670, gttgctctgtgttaagttaacatggg/gttagtcctaaatgtcttgattgcc). Brightfield 
images of in situ hybridizations and worm morphology/movement were imaged using a Zeiss AxioZoom 
V16 (Zeiss, Germany) equipped with a transmitted light base and a Zeiss AxioCam 105 Color camera. 
Fluorescent images were acquired using a Nikon A1+ laser scanning confocal microscope. For worm length 
quantification, phalloidin-stained male worms (13 days post-RNAi) were imaged and worm length 
measured using NIH ImageJ, Fiji distribution (26). 
 
Transplantation of dsRNA-treated Schistosomes 
Parasites 4–5 weeks post-infection were recovered from mice and treated with 30 µg/mL dsRNA for 4 days 
in Basch Media 169 with a daily replacement of media and dsRNA and surgically transplanted into naïve 
male mice as previously described (27). Briefly, 10 pairs of adult worms were loaded into a syringe and 
injected into the cecal vein of a young male Swiss Webster mice (~25–30 g), then the syringe was flushed 
to determine how many parasites were injected.  On day 26 post-transplantation, mice were sacrificed and 
perfused to recover parasites. Male and female parasites were counted and livers were removed and fixed 
for 30–40 hours in 4% formaldehyde in PBS. The percentage of parasite recovery was determined by 
dividing the number of male worms transplanted by the number of male parasites recovered following 
perfusion. Livers from individual mice were sectioned and processed for Hematoxylin and Eosin staining 
by the UT Southwestern Molecular Pathology Core. 
 
Detection of polyubiquitinated proteins by western blot 
For RNA interference, 10 single-sex male adult worms (6 weeks post infection) were treated with 30 µg/mL 
dsRNA in Basch Media 169 for 8 days. Media and dsRNA were changed daily. On day 9, worms were 
collected and flash frozen. For drug treatment, 10 male adult worms (single or paired with females) were 
supplemented with either DMSO, NMS-873 or CB-5083. After 24 hrs, male parasites were separated from 
females using 0.25% tricaine in Basch Media 169 and flash frozen. Male worm samples were homogenized 
with a pestle in 50 µL lysis buffer containing 2× sample buffer, protease inhibitor cocktail (Roche, 
cOmplete Mini, EDTA-free Tablets) and 10mM DTT. The lysates were then sonicated on high for 5 min 
(30 sec on, 30 sec off) using a Bioruptor UCD-200. Lysates were centrifuged for 5 min at 10,000 g to 
remove debris. Total protein was measured using the Detergent Compatible Bradford Assay (Pierce). 35 µg 
of protein samples denatured in SDS Sample buffer (95°C for 5min) were separated on a Bio-Rad 4-20% 
TGX Stain-Free gel along with Precision Plus Protein Dual Color Standards (Bio-Rad) as a marker. Proteins 
were then transferred to a nitrocellulose membrane (Bio-Rad) and confirmed by Ponceau S staining. The 
membrane was blocked in a 1:5 solution of Li-Cor Odyssey Blocking buffer in PBS for 1hr before being 
immunoblotted overnight at 4°C with 1:500 K48-linkage Specific Polyubiquitin Antibody (Cell Signaling 
Technology, 4289S) and 0.01 µg/mL mouse anti-actin antibody (Developmental Studies Hybridoma Bank, 
JLA20) diluted in a 1:5 solution of Li-Cor Odyssey Blocking buffer in PBS. The membrane was washed 
3× in TBST and then incubated in 1:5 Li-Cor Odyssey Blocking buffer containing the secondary antibodies 
(1:10,000 Li-Cor, 925-68071, goat anti-rabbit IRDye 680 RD, and 1:20,000 Li-Cor, 925-32280, goat anti-
mouse IgM IRDye 800CW) for 1hr at RT. The blot was washed in TBST 3× before being imaged on a Li-
Cor Odyssey Infrared Imager. 
 
Compound prioritization 
To manually search for existing drugs targeting “detachment” hits from our RNAi screen, we performed 
protein-protein BLAST against the Homo sapiens proteome to find the closest human homolog to our RNAi 
hits. We then manually searched a variety of databases (e.g., GeneCards, Google, DrugBank, Therapeutic 
Targets Database) and chemical vendors (e.g., Selleckchem) for inhibitors against these human proteins.  
In each instance, we consulted the published literature to give preference to compounds likely to be selective 
for a given target.  If several such drugs were available, preference was given to those that were also orally 
 
 
bioavailable and/or FDA approved/in clinical trials.  For larger-scale discovery of compounds, the S. 
mansoni protein sequences of genes with ‘detachment’ phenotypes were used to search the ChEMBL 
database (9), to identify compounds predicted to interact with them. To do this, we followed the protocol 
previously described (28) with the following differences. First, for each S. mansoni gene, we identified its 
top BLASTP hit among all ChEMBL targets, as well as any ChEMBL targets having BLAST hits with E-
values within 105 of the top hit’s E-value; and then extracted from ChEMBL the drugs/compounds with 
bioactivities against those particular ChEMBL targets. Second, when calculating the ‘toxicology target 
interaction’ component of a compound’s score, we checked whether ChEMBL predicted with probability 
>0.5 that the compound interacts with one of 108 toxicology targets curated from (29-31). 
 
Evaluation of effects of compounds on worms 
in vitro evaluation of selected compounds (single-point concentrations, 10 µM in 0.1% DMSO) on adult 
movement was replicated three times using a single worm pair per well (two technical replicates each time, 
n = 12), as previously described (32).  Worm pairs co-cultivated with DMSO (0.1% negative control) and 
Praziquantel (PZQ) (10 µM in 0.1% DMSO; positive control) were included in each experiment. Following 
incubation at 37˚C for 72 hrs in a humidified atmosphere containing 5% CO2, a digital image processing-
based system was used for the assessment of parasite motility. Both hardware and software components of 
this system (WormassayGP2) were inspired by the digital macroscopic imaging apparatus previously 
described (33), with minor modifications to the source code (supporting USB video class, UVC, camcorders 
and the High Sierra MacOS) and user interface (allowing manual manipulations to recording duration).  A 
dose-response titration (10 µM – 0.156 µM) of CB-5083 and NMS-873 was performed to assess adult worm 
anti-schistosomal potencies. Each titration point was performed in triplicate (a pair of worms for each 
replicate). Worm movement was recorded with WormassayGP2, as mentioned above. Mean motility scores 
were calculated for each titration point and dose-response curves were derived in comparison to worms co-
cultured in DMSO (0.1% v/v; negative control; 100% motility) and PZQ (10 µM in 0.1% DMSO; positive 
control; 0% motility). Anti-schistosomula activities of the selected compounds were assessed using the 
high-content imaging platform Roboworm as previously described (32, 34). Compounds (reconstituted in 
dimethyl sulfoxide, DMSO; 10 mM stock concentration) were initially tested at two different concentration 
points (10 µM and 50 µM, in 0.625% DMSO) along with negative (0.625% DMSO) and positive controls 
(PZQ at 10 µM final concentration in 0.625 % DMSO). Schistosomula/compound co-cultures were then 
incubated at 37oC for 72 h in a humidified atmosphere containing 5% CO2 before phenotype and motility 
metrics were assessed.  Two-fold titrations (10 µM, 5 µM, 2.5 µM, 1.25 µM and 0.625 µM) were 
subsequently conducted for all compounds consistently identified as hits at 10 µM in the primary screens. 
Single point schistosomula screens (10 µM) were repeated three times whereas dose response titrations 
were performed twice (in each screen two technical replicates were included).  Phenotype and motility 
scores deriving from the titration of each compound were collected to generate approximate EC50s using 
GraphPad Prism.  To quantify adult worm attachment to the substrate following drug treatment, freshly 
perfused adult worms were sorted into a 6-well plate with 3 mL Basch 169 media and cultured overnight.  
The following day (D0) unattached worms removed and compounds were added to the media to a final 
concentration of 10 µM.  Media and drug were replaced on D1 and D2.  Media with no drug was added on 
D3 and D5.  Parasite attachment was monitored from D0 to D7.   
 
RNAseq for stk25 and tao RNAi-treated worms 
To examine gene expression changes following loss of tao or stk25, 10 adult worm pairs were placed into 
6-well plates and cultured in 3 mL Basch 169 supplemented with 30 µg/mL dsRNA for 3 days. Media and 
dsRNA were replaced daily. On D3, dsRNA-containing media was removed and worms were maintained 
in 6 mL Basch 169 media that was replaced every other day.   On day 6 (tao(RNAi)) or D9 (stk25(RNAi)) 
worms were anesthetized with 0.25% tricaine and separated by sex.  As controls, worms cultured in parallel 
were treated with an irrelevant dsRNA (2).  Three biological replicates were performed for each knockdown 
condition and their respective control treatment.  For RNA extraction, male worms were collected, excess 
media removed, and 100 µL of TRIZOL was added.  Parasites were then flash frozen in liquid N2, 
 
 
homogenized with a micro pestle, the volume of TRIZOL was brought to 600 µL before RNA was purified 
using a Zymo Direct-zol RNA miniprep kit and processed for Illumina sequencing.  RNAseq data across 
the three biologically independent replicates for each knockdown set was mapped to the S. mansoni genome 
(v7) using STAR and differential expression was analyzed by DESeq2 as previously described (35).  Raw 
data can be accessed in NCBI under the accession number GSE146720.  To define the correlation between 
genes differentially regulated following RNAi of tao and/or stk25, we compiled a list of all genes that had 
significantly changed expression in either stk(RNAi) or tao(RNAi) datasets and plotted their log2 fold-
change expression in GraphPad Prism to calculate a Pearson correlation coefficient.  To evaluate the effects 
of tao and stk25 RNAi on gene expression in specific tissues and cell types we collapsed related cell types 
from a S. mansoni single cell atlas (17) into 10 broad clusters of somatic cell types found in male worms 
(muscles, neurons, neoblasts, gut, etc.) (Fig. S10B).  Genes highly enriched in these clusters were 
determined using Seurat v3.1.1(36) (parameters = logfc.threshold = 1, min.pct = 0.5) and compared to genes 
down-regulated (p adj < 0.000001) following both tao and stk25 RNAi.  
 
Purification of Recombinant STK25 and TAO  
Baculovirus expressing wildtype Schistosoma mansoni Smp_068060 (TAO) or Smp_096640 (STK25) with 
a C-terminal His6 tag was generated by GenScript (Piscaaway, NJ).  cDNA encoding kinase-dead versions 
of both kinases were subcloned into the pFastBac1 vector with C-terminal His6 tag and baculovirus was 
generated according to the manufacturer’s instructions using the Bac-to-Bac Baculovirus Expression 
System (Invitrogen).  Baculovirus was used as a 3rd pass virus to infect Sf9 cells grown in Gibco Sf 900 III 
SFM (Thermofisher Scientific) supplemented with 1% FBS and Antibiotic-Antimycotic solution (Sigma-
Aldrich). Cells were harvested 72 hrs post infection for SmSTK25 expression and 48 hrs post infection for 
SmTAO expression. Frozen cell pellets were lysed with 20 mM Tris, pH 8.0, 5 mM MgCl2, 300 mM NaCl, 
1% Triton X-100 (Fisher Scientific), DNase (24 µg/mL), 10% glycerol, 3 mM 2-mercaptoethanol, and 
protease inhibitors (1 µg/mL aprotinin, 2 µg/mL leupeptin, 1 mM benzamidine, and 0.2 mM PMSF). After 
homogenization, the suspension was centrifuged for 1 h at 186,000 × g and the supernatant was rotated with 
Ni2+-NTA resin (Qiagen) for 1.5 hrs. The resin was washed, and the protein was eluted in 20 mM Tris, pH 
8.0, 5 mM MgCl2, 300 mM NaCl, 0.05% Triton X-100, 10% glycerol, 3 mM 2-mercaptoethanol, 150 mM 
Imidazole, pH 8.0 and protease inhibitors (1 µg/mL aprotinin, 2 µg/mL leupeptin, 1 mM benzamidine, and 
0.2 mM PMSF). Eluted proteins were either flash frozen or further dialyzed overnight into storage buffer 
(20 mM Tris, pH 8.5, 5 mM MgCl2, 150 mM NaCl, 0.5 mM DTT, 10% glycerol, and 1 mM benzamidine) 
and flash frozen to -80°C.  
 
To generate an anti-SmSTK25 antibody, a C-terminal fragment of SmSTK25 corresponding to AA513-622 
was amplified and sub-cloned into pET28 vector with a C-terminal His6 tag for expression in Escherichia 
coli.  This fragment was purified from transformed Rossetta 2 cells grown in LB medium and induced with 
1mM isopropyl 1-thio-b-D-galactopyranoside for 16 hrs at 18°C. Cells were pelleted and resuspended into 
lysis buffer containing 50 mM Tris, pH8.0, 300 mM NaCl, 10% glycerol, and protease inhibitors (0.2 mM 
PMSF, 2 µg/mL aprotinin, and 2 µg/mL leupeptin). The suspension was freeze-thawed and the following 
reagents were added to a final concentration of 1 mg/mL lysozyme, 1% Triton X-100, 5 µg/mL DNase. 
After homogenization and sonication, lysate was centrifuged for 40 min at 186,000× g, and rotated with 
Ni2+-NTA resin for 1.5 hrs. The resin was washed, and protein was eluted in lysis buffer containing 300 
mM imidazole. SmSTK25 (513-622) was buffer-exchanged into 1× PBS and 10% glycerol and applied to 
a Superdex 200 column for gel filtration chromatography on an AKTA FPLC. The sample was processed 
at a flow rate of 0.9 mL/min in 1× PBS and 10% glycerol. Eluate was collected as 90 1-mL fractions on a 
Frac 900 fraction collector (Amersham Pharmacia) maintained at 4°C. Each fraction was assessed for 
protein and concentrated with an Amicon concentrator, 10-kDa cut-off (Millipore).  Rabbit polyclonal 
antibodies were generated by Cocalico Biologicals, Inc and confirmed to recognize the recombinant 




Evaluation of kinase activity 
For kinase assays with radiolabeled ATP, STK25 or STK25K48R (1.7 µM) were incubated alone or 
together with either TAO or TAOK57R (0.3 µM) and 50 µM ATP ([g-32P]ATP, 6,000-9,000 cpm/pmol) in 
10 mM Tris, pH 8.0, and 10 mM MgCl2 for 10 min at 30°C. Following gel electrophoresis and 
autoradiography, STK25 or STK25K48R (1.25 µM) as well as TAO or TAOK57R (0.25 µM) bands were 
excised and analyzed by scintillation counting (Perkin Elmer, Tri-Carb 2910TR).  For evaluation of STK25 
phosphorylation by western blotting, proteins were incubated for 30 mins at 30°C in kinase assay buffer 
(10 mM Tris pH 8.0, 10 mM MgCl2, 0.5 µM per protein) with or without 50 µM ATP in a reaction volume 
of 30 µL. Reactions were quenched with 10 µL of 4× Laemmli buffer and samples boiled at 99°C for 4 
min, then stored at -20°C.  Proteins were resolved by SDS-PAGE (Bio-Rad 4-20% precast polyacrylamide 
gel, cat# 4568095) for 45 min at 140 V. The gel was placed in cold transfer buffer (25 mM Tris, 192 mM 
Glycine, 10% (v/v) methanol, pH ~8.4) and transferred to a nitrocellulose membrane (Bio-Rad cat# 
1620115) for 60 min at 100 V, 4°C. The membrane was stained with Ponceau S Solution (Sigma cat# 
P7170) for 5 min, imaged and destained by 2× washes with TBST (20 mM Tris, 150 mM NaCl, 0.1% (v/v) 
Tween20). The membrane was blocked for 1 hr at RT with blocking buffer (Odyssey Blocking Buffer, Li-
Cor cat# 927-40000) diluted 1:5 in TBS (20 mM Tris, 150 mM NaCl)), then stained O/N at 4°C with 
primary antibody diluted in blocking buffer. Membrane was washed 3× 5 min with TBST, then stained with 
secondary antibody diluted in blocking buffer, 1 hr at RT. Membrane was washed 3× 5 min with TBST, 
then imaged with a LI-COR Odyssey imaging system. Primary antibodies were as follows: to detect 
phosphorylated T173 of smSTK25 and kinase-dead smSTK25, we used Rabbit-anti-MST4 + MST3 + 
STK25 (phospho T174 + T178 + T190) antibody [EP2123Y] (ab76579) from Abcam. To detect total 
smSTK25 and kinase-dead smSTK25 we used the Rabbit polyclonal antibody against the STK25 C-
terminus described above. Secondary antibody for all blots was LI-COR IRDYE 680 red, Goat anti-Rabbit 
cat# 925-68071, and was used at a dilution of 1:10,000.   
For mass spectrometry analyses of SmTAO phosphorylation of kinase-dead SmSTK25, kinase 
reactions were performed as above, and the SmSTK protein was excised from an SDS-PAGE gel and the 
protein was analyzed by the UT Southwestern Proteomics Core. Specifically, protein gel pieces were 
digested overnight with trypsin (Pierce) following reduction and alkylation with DTT and iodoacetamide 
(Sigma–Aldrich). The samples then underwent solid-phase extraction cleanup with Oasis HLB plates 
(Waters) and the resulting samples were analyzed by LC/MS/MS, using an Orbitrap Fusion Lumos mass 
spectrometer (Thermo Electron) coupled to an Ultimate 3000 RSLC-Nano liquid chromatography systems 
(Dionex). Samples were injected onto a 75 µm i.d., 75-cm long EasySpray column (Thermo), and eluted 
with a gradient from 1-28% buffer B over 90 min. Buffer A contained 2% (v/v) ACN and 0.1% formic acid 
in water, and buffer B contained 80% (v/v) ACN, 10% (v/v) trifluoroethanol, and 0.1% formic acid in water. 
The mass spectrometer operated in positive ion mode with a source voltage of 1.8 kV and an ion transfer 
tube temperature of 275 °C. MS scans were acquired at 120,000 resolution in the Orbitrap and up to 10 
MS/MS spectra were obtained in the ion trap for each full spectrum acquired using higher-energy collisional 
dissociation (HCD) for ions with charges 2-7. Dynamic exclusion was set for 25 s after an ion was selected 
for fragmentation.  Raw MS data files were converted to a peak list format and analyzed using the central 
proteomics facilities pipeline (CPFP), version 2.0.3 (37, 38). Peptide identification was performed using 
the X!Tandem (39) and open MS search algorithm (OMSSA) (40) search engines against the S. mansoni 
protein database from Uniprot, with common contaminants and reversed decoy sequences appended (41). 
Fragment and precursor tolerances of 10 ppm and 0.6 Da were specified, and three missed cleavages were 
allowed. Carbamidomethylation of Cys was set as a fixed modification with oxidation of Met and 
phosphorylation of Ser, Thr, and Tyr set as variable modifications. Phosphorylation sites were localized 
using the ModLS algorithm, using cutoff values for positive site identification that represent a scenario 
where the false discovery rate is < 1% (42). 
 
Gene Ontology (GO) 
 
 
The Gene Ontology (GO) annotation for Schistosoma mansoni was obtained from GeneDB 
(https://www.genedb.org/). GO term enrichment was performed using the weight01 method provided in 
topGO (v2.34.0) for biological process (BP), molecular function (MF) and cellular component (CC). GO 
term enrichment was performed by comparing hits with the entire list of 2,216 screened genes. For each 
category, the analysis was restricted to terms with a node size of >= 5. Fisher's exact test was applied to 
assess the significance of overrepresented terms compared with the screened genes. The threshold was set 
as FDR < 0.05.  
 
Identification of S. mansoni-specific phenotypes 
For data in Table S5, close homologs of S. mansoni genes in C. elegans, D. melanogaster and human 
were identified as C. elegans or D. melanogaster genes belonging to the same gene family, or listed as 
orthologs, in WormBase ParaSite v14 (43). We considered S. mansoni and Schmidtea mediterranea genes 
(taking the dd_Smed_v6 gene set from PlanMine (44)) to be one-to-one orthologs if they were each 
other’s top BLASTP hits, with E-value < 0.05, and the BLAST E-value of the top BLASTP hit was 105 
times lower than the BLAST E-value for the next best hit. C. elegans RNAi/mutant phenotypes were 
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Fig. S1
Fig. S1. Large-scale RNAi screening in S. mansoni. (A) Pipeline for large-scale RNAi screening 
. (B) An example of strategy for a single gene from the initial RNAi screen and the subsequent val-
idation. PCR primers for the initial screening were modified by adding sequences including restric-
tion enzyme sites (NotI on forward primer, AscI on reverse primer) and a T7 polymerase promoter 
on both forward and reverse primers.  To validate PCR product sequences we digested with NotI 
and the amplicon was sequenced with a T7 primer. To validate the initial screening results, in 129 
cases we cloned a cDNA fragment that did not overlap with the initial amplicon.  In 132 cases we 
assessed potential off-target effects by BLAST searching against the S. mansoni transcriptome. 
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Fig.S2. All 66 hits with phenotypes of loss of stem cell maintenance. EdU labeling of proliferative 
cells in somatic tissues and the testes is shown in yellow, parasites are counterstained with DAPI to 
mark nuclei. RNAi of DNA polymerase epsilon subunit (Smp_124120) leads to loss of all proliferative 
cells, whereas rad51 (Smp_124230) or fgfrA (Smp_175590) lead to a selective reduction in the testes 
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Fig. S3. Gene Ontology (GO) analysis. (A) GO analysis of all the 66 genes with a loss of stem 
cells phenotype. (B) GO analysis of all the 195 genes with a detachment phenotype.  GO term en-
richment was performed by comparing hits with the entire list of 2,216 screened genes. All enriched 
GO terms with the threshold FDR< 0.05 are listed for Biological Process (BP), Molecular Function 
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Fig. S4. Phenotypes of RNAi-treatment for various ubiquitin-proteasome system (UPS) 
components. (A) A large fraction of genes resulting in visible phenotypes were associated with 
components of the Ubiquitin Proteasome System (UPS).  In the cartoon of the UPS, colored 
components correspond to genes associated with visible phenotypes. (B) List of genes associated 
with visible phenotypes and the component of the UPS they encode. (C) RNAi of the listed UPS 
components in our 30-day treatment regime resulted in degeneration of the parasite’s tegument 
or detachment from the substrate. Uch5 (Smp_069960) , a ubiquitin carboxyl-terminal hydrolase 5 


































































































Fig. S5. Evaluation of p97/proteasome inhibitors. (A) EC50 values for the p97 inhibitors CB-5083 
and NMS-873 on parasite movement.  Error bars represent standard deviation of the mean motil-
ity scores (as percentages).  n= 6 (three biological replicates, single adult worm pair/well for each 
concentration point). (B) Western Blot for K48-linked polyubiquitinated proteins. Representative from 
3 experiments. (C) Western Blot for K48-linked polyubiquitinated proteins. RNAi of S. mansoni p97 
or treatment of worms with the p97 inhibitors caused an increase in the accumulation of K48-poly-
ubiquitinated proteins.  Representative from 3 experiments. (D) Western Blot for K48-linked 
polyubiquitinated proteins. RNAi of S. mansoni proteasome subunit beta type-2 or treatment of 
worms with the proteasome inhibitor Ixazomib caused an increase in the accumulation of K48-
polyubiquitinated proteins. Treatment of worms with non-UPS inhibitor thapsigargin, which also 
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Fig. S6
Fig. S6. In vivo validation of RNAi hits by surgical transplantation. (A) Strategy for in vivo 
validation. Parasites were perfused from mice at 4-5 weeks after infection and then treated with 
30 μg/mL dsRNA for 4 days before surgical transfer into the mesenteric veins of naive mice. After 
26 days, mice were sacrificed to harvest worms and livers. (B) Percent recovery of male parasites 
treated with dsRNA specific to proteasome subunit beta type-2 (psmb2, Smp_074500; n = 10 
transplants) or an irrelevant dsRNA (control; n = 8 transplants) following surgical transplantation 
of parasites into mice. ****, p < 0.0001, t-test. (C) Liver morphology of mice after transplantation of 
worms that were pretreated with control dsRNA, proteasome subunit beta type-2 (psmb2) or p97 
. Granulomas were only observed in mice receiving control parasites. (D) Hematoxylin and Eosin 
staining of livers from recipient mice that received either control or psmb2 (RNAi).  Schistosome 
egg-induced granulomas (indicated by yellow arrows) in livers were observed in control RNAi re-
cipient mice, but not in psmb2 (RNAi) recipient mice.  Counts of eggs per liver section are shown 
in top right, n=3. (E-F) Transplanted parasites (indicated by yellow arrows) from RNAi treament of 
either proteasome psmb2 (E) or p97 (F) were found trapped and in various stages of degeneration 
in livers of recipient mice. Scale bars, 100 μm. 
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Fig. S7
Fig. S7. Attachment curve of stk25/tao RNAi parasites in vitro and surgical transplantation of 
stk25/tao RNAi parasites. (A) dsRNA treatment of S. mansoni targeting either stk25 or tao caused 
the worms to detach from Petri dish starting at 6 days after in vitro cultivation. cntl, control. n=9 for 
each group with 3 replicates. Error bars represent 95% confidence intervals. (B) stk25 and tao 
RNAi-treated parasites are shorter than control RNAi-treated worms. >19 parasites monitored over 
4 experiments.  p < 0.0001, t-test.  (C-D), Hematoxylin and Eosin staining of livers from recipient 
mice that received either cntl or stk25 (RNAi) or tao (RNAi). Egg-induced granulomas (indicated by 
yellow arrows) were only observed in control group. n=3. Scale bars, 100 μm.
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Fig. S8. Assays of Schistosoma mansoni protein kinases STK25 and TAO. (A) Autoradiogra-
phy of a kinase assay with recombinant schistosome proteins. Wild type SmTAO protein phosphor-
ylates both wild type and kinase-dead SmSTK25, and that signal is ablated when wild type SmTAO 
is replaced by a kinase-dead mutant (kdSmTAO, K57R). (B) Quantification of radioactive 
phosphate transfer in kinase assay shown in (A), by scintillation counting. Results from n = 2 
technical replicates (C) High confidence phosphosites of SmSTK25 kinase from mass 
spectrometry. To determine high confidence sites, only those with ModLS scores >30 and ID prob 
>0.95 on the PTM (post-translational modification) report were chosen. Eight high confidence 
phosphosites were de-tected and shown on the cartoon. (D) Sequence alignment of S.mansoni 
STK25 kinase SmSTK25 activation segment and its human homologue HsSTK25 as well as 
Drosophila homologue DmG-CKIII. Threonine 173 (T173) indicated in red box is the phosphosite in 
the activation segment highly conserved in different organisms. The positions of amino acids on 
SmSTK25 were used. (E) Align-ment of amino acids surrounding the VAIK motif required for 
catalysis in most kinases. To make kinase dead versions of SmSTK25 and SmTAO, the catalytic 
lysine in the VAIK motif was mutated to arginine (K48R and K57R for SmSTK25 and SmTAO, 












































































































































High confidence phosphosites from mass spectrometry PTM report.

























































Fig. S9.RNA-seq and data analysis of the differentially expressed genes in stk25/tao RNAi. (A 
-B) RNAseq strategy for male worms treated with dsRNA that target either tao or stk25. (C) Anal-
ysis of the differentially expressed genes after stk25 or tao RNAi. Genes with low expression level
(baseMean≤ 10) were excluded before further analysis. Among the 8,237 genes that are both ex-
pressed in stk25 and tao datasets indicated by Venn diagram, 1,775 genes and 2,249 genes were
significantly differentially expressed (padj <0.05) in either stk25 RNAi or tao RNAi compared with
control RNAi worms. Of the 998 and 1,231 down-regulated genes (Log2FC <0, padj <0.05) in stk25
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Fig. S10. Ratio of somatic markers in down-regulated genes in stk25/tao RNAi worms.  (A) 
Dimensional reduction plot of somatic tissue clusters from an adult single cell atlas. Each dot rep-
resents a cell and cells from the same cluster were labeled with same color. (B) Percentage of 
tissue-specific somatic markers down-regulated (padj < 0.000001) after stk25 or tao RNAi treatment, 
measured by RNAseq.  Nearly half of all muscle-specific markers are down-regulated in both stk25 
or tao RNAi treatment groups. teg stands for tegument. (C) Dotplot showing the expression of the 
top 129 down-regulated (Log2 Fold Change <-0.5, adjusted p-value < 0.00001) genes in common 
to both stk25 and tao RNAi datasets across somatic tissues.  Most down-regulated genes are ex-
pressed in muscles.  (D) Scatter plot showing the relationship between all muscle-specific genes 
with baseMean>10 following either stk25 or tao RNAi-treatment . These expression profiles were 




















Fig. S11. Phalloidin staining of male parasites after RNAi treatment with either control 
(cntl), tao or stk25 dsRNA. No obvious differences in muscle fiber morphology or numbers by 
phalloidin labeling were observed between cntl RNAi or tao/stk25 RNAi worms in either 
anterior (head) or posterior (body) parts of the worm body. Representative from n = 4 biological 
replicates Scale bar, 10 μm.
 
 
Captions for Tables S1-S10 (Tables are located in separate excel files)  
 
Table S1. Information of 2,320 genes selected for RNAi screening.    
Table S2. Details of 195 genes with detachment phenotypes. 
Table S3. Details of 66 genes with phenotypes in EdU incorporation.  
Table S4. Similarity of schistosome genes with phenotypes with gene products from other 
organisms by BLAST (E-value < 0.05) or orthologs present in Wormbase Parasite (S. japonium 
and S. haematobium).   
Table S5. S. mansoni genes with detachment phenotypes compared to phenotypes of genes from 
C. elegans and D. melanogaster in WormBase/FlyBase 
Table S6. S. mansoni RNAi hits and their potential inhibitors. 
Table S7. Details of 14 selected inhibitors to test on schistosomes. 
Table S8. Evaluation of compound activity on schistosomula  
Table S9. Analysis of transcriptional changes following stk25 or tao RNAi treatment by DESeq.  
Second tab shows in which somatic cell clusters the most down-regulated (p<0.00001 Log2 Fold 
Change <-0.5) genes following stk25 or tao RNAi treatment are expressed.   
Table S10.  Analysis of expression of somatic tissue-specific markers following stk25 or tao RNAi 
treatment.  Tissue-specific markers down-regulated (Log2 Fold Change < 0 and p adj < 0.000001) 






Captions for Movies S1-S4 (Movies are located in separate .mov file) 
 
Movie S1. Adult worms after 30 days of in vitro treatment with control dsRNA. On day 30, 
worms were physically active and firmly attached to the bottom of the dish. 
Movie S2. Effects of various compounds on parasites.  Parasites were treated with compounds 
for 72 hours at a concentration of 10 µM.  We observed various worm defects ranging from death, 
to tissue degeneration, and detachment from the substrate.  DMSO and PZQ were used as negative 
and positive controls, respectively. 
Movie S3. Parasites died in 72 hours in vitro following treatment with CB-5083 or NMS-873. 
Adult worms were dead following 72 hours of treatment with 1 µM CB-5083 or 5 µM NMS-873. 
Tegumental damage was observed on these worms. DMSO was used as a control.  
Movie S4. stk25/tao RNAi treated worms become hypercontracted and paralyzed by D13 
following dsRNA treatment. 
  
